- Study Looks at Caffeine Use, Exercise Pain
- Diabetes Drug Candidate Appears Safe: FDA
- U.S. Task Force Urges Docs to Screen for Depression in Teens
Here are some of the latest health and medical news developments, compiled by editors of HealthDay:
Study Looks at Caffeine Use, Exercise Pain
The same degree of caffeine-related pain reduction during exercise occurs both in people who normally consume a lot of caffeine and in those with little or no caffeine intake, according to a U.S. study.
It included 25 fit, college-age males who were divided into two groups -- those who had a caffeine intake of about 400 milligrams per day (equal to three or four cups of coffee) and those who normally consumed little or no caffeine, United Press International reported.
The participants did two high-intensity, 30-minute exercise sessions. They were told not to consume caffeine for 24 hours prior to the sessions. One hour before each session, the participants were given a pill. On one occasion, the pill contained a placebo, and the other time, it contained 5 milligrams of caffeine per kilogram of body weight, about the same as two to three cups of coffee.
"What's interesting is that we found that caffeine tolerance doesn't matter, we were perplexed at first," study author Robert Motl, a professor of kinesiology and community health at the University of Illinois, said in a news release, UPI reported.
"Then we looked at reviews of the literature relative to caffeine and tolerance effects across a variety of other stimuli. Sometimes you see them, sometimes you don't. That is, sometimes regular caffeine use is associated with a smaller response, whereas, other times, it's not," Motl said.
The study was published in the April issue of the International Journal of Sport Nutrition and Exercise Metabolism.
Diabetes Drug Candidate Appears Safe: FDA
A potentially important diabetes medication called Onglyza appears to be free from heart-related side effects seen in similar treatments, according to U.S. Food and Drug Administration briefing documents posted online.
An FDA panel of outside experts will meet Wednesday to review safety data on the drug, the Associated Press reported. The panel will then make a recommendation on whether the drug should be approved for use in the United States.
The FDA, which generally follows the advice of its expert panels, could make a decision about Onglyza by the end of April.
Bristol-Myers Squibb and partner AstraZeneca are seeking approval to market Onglyza to reduce blood sugar levels in patients with type 2 diabetes, the AP reported.
Studies conducted by the companies indicate the level of heart attacks, deaths and other cardiovascular problems appeared well within new FDA safety limits, the agency said in the briefing documents.
U.S. Task Force Urges Docs to Screen for Depression in Teens
Primary care doctors should routinely screen adolescents, ages 12 to 18, for major depression, says the U.S. Preventive Services Task Force. The benefits of screening outweigh any risks if doctors can assure accurate diagnosis, treatment and follow-up, according to the task force.
That's a change from 2002, when the task force concluded there wasn't sufficient evidence to recommend or oppose screening for adolescents. The task force said there's still not enough evidence to make a recommendation about depression screening for children ages 7 to 11, USA Today reported.
In an article in the journal Pediatrics, the task force noted that questionnaires can accurately identify depression in adolescents, and that there's new evidence that therapy and/or some antidepressants can help depressed teens. They emphasized the need for careful monitoring, because it's been shown that antidepressants can increase suicidal behavior in teens.
About 1 in 20 teens suffers depression, which is associated with lower grades, more physical illness, increased drug use, and early pregnancy, USA Today reported.
Copyright © 2011 HealthDay. All rights reserved.